Famotidine Tablet
NDC 37835-161
Product Information
Famotidine is a ANDA-approved product labeled by Bi-mart. Famotidine is used to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 37835-161 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
V;21
Code Structure Chart
Product Details
What is NDC 37835-161?
What are the uses of this product?
What are Active Ingredients of this product?
- FAMOTIDINE 10 mg/1 - A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- FAMOTIDINE (UNII: 5QZO15J2Z8)
- FAMOTIDINE (UNII: 5QZO15J2Z8) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- STARCH, CORN (UNII: O8232NY3SJ)
- SODIUM STARCH GLYCOLATE TYPE A (UNII: H8AV0SQX4D)
- HYDROXYPROPYL CELLULOSE, UNSPECIFIED (UNII: 9XZ8H6N6OH)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- HYPROMELLOSE, UNSPECIFIED (UNII: 3NXW29V3WO)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- TRIACETIN (UNII: XHX3C3X673)
- POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)
- TALC (UNII: 7SEV7J4R1U)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 199047 - famotidine 10 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.